Skip to main content

Table 3 Distribution of study outcomes in COPD/CB patients during one year prior to baseline

From: Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study

Outcome variable Categories Female
N = 47,487 (53.6%)
Male
N = 41,061 (46.4%)
P-value Total
N = 88,548 (100%)
All cause hospitalizations   0.97 ± 1.78 1.08 ± 1.98 <0.001 1.02 ± 1.88
0 27,540 (58.0) 23,172 (56.4)   50,712 (57.3)
1-2 14,105 (29.7) 12,145 (29.6) 26,250 (29.6)
3-5 4500 (9.5) 4331 (10.5) 8831 (10.0)
>5 1342 (2.8) 1413 (3.4) 2755 (3.1)
All cause secondary care out-patient visits   2.82 ± 5.28 3.01 ± 7.45 <0.001 2.91 ± 6.38
0 13,600 (28.6) 11,812 (28.8)   25,412 (28.7)
1-2 16,333 (34.4) 13,941 (34.0) 30,274 (34.2)
3-5 10,674 (22.5) 9303 (22.7) 19,977 (22.6)
>5 6880 (14.5) 6005 (14.6) 12,885 (14.6)
Respiratory hospitalizations   0.27 ± 0.89 0.27 ± 0.87 0.273 0.27 ± 0.88
0 40,224 (84.7) 34,857 (84.9)   75,081 (84.8)
1-2 6070 (12.8) 5167 (12.6) 11,237 (12.7)
3-5 953 (2.0) 865 (2.1) 1818 (2.1)
>5 240 (0.5) 172 (0.4) 412(0.5)
Systemic corticosteroid purchases   1.28 ± 4.19 0.99 ± 3.34 <0.001 1.15 ± 3.82
0 32,141 (67.7) 29,932 (72.9)   62,073 (70.1)
1-2 8935 (18.8) 6530 (15.9) 15,465 (17.5)
3-5 4112 (8.7) 3024 (7.4) 7136 (8.1)
>5 2299 (4.8) 1575 (3.8) 3874 (4.4)
Systemic antibiotic purchases   1.60 ± 2.90 1.24 ± 2.34 <0.001 1.44 ± 2.66
0 20,827 (43.9) 20,833 (50.7)   41,660 (47.0)
1-2 17,029 (35.9) 13,867 (33.8) 30,896 (34.9)
3-5 6814 (14.3) 4716 (11.5) 11,530 (13.0)
>5 2817 (5.9) 1645 (4.0) 4462 (5.0)
  1. Numbers presented as N (%) or as mean ± SD. P-value for difference in mean values between genders
  2. Abbreviation: SD Standard deviation